The osterix transcription factor down-regulates interleukin-1α expression in mouse osteosarcoma cells

Molecular Cancer Research

Volumn 6, Issue 1, 2008, Pages 119-126

  Cao, Ying ^a   Jia, Shu Fang ^a   Chakravarty, Geetika ^a   De Crombrugghe, Benoit ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; OSTEOPROTEGERIN; PROSTAGLANDIN E2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS;

ANIMALS; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-1ALPHA; MALE; MICE; MICE, INBRED BALB C; MUTATION; OSTEOPROTEGERIN; OSTEOSARCOMA; PHENOTYPE; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 40749157096     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0090     Document Type: Article

References (21)

1. Ragland BD, Bell WC, Lopez RR, et al. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 2002;82:365-73.
2. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75:203-10.
3. Bathurst N, Sanerkin N, Watt I. Osteoclast-rich osteosarcoma. Br J Radiol 1986;59:667-73.
4. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002;108:17-29.
5. Cao Y, Zhou Z, de Crombrugghe B, et al. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res 2005;65:1124-8.
6. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
7. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
8. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
9. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
10. Myers DE, Collier FM, Minkin C, et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 1999;463:295-300.
11. Green EA, Flavell RA. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med 1999;189:1017-20.
12. Ross FR. RANKing the importance of measles virus in Paget's disease. J Clin Invest 2000;105:555-8.
13. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998;23:75-81.
14. Pacifici R. Aging and cytokine production. Calcif Tissue Int 1999;65:345-51.
15. 3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998;246:337-41.
16. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/ OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
17. Dinarello AC. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-25.
18. Huang TT, Vinci JM, Lan L, et al. Serotonin-inducible transcription of interleukin-1α in uterine smooth muscle cells requires an AP-1 site: cloning and partial characterization of the rat IL-1α promoter. Mol Cell Endocrinol 1999;152:21-35.
19. Cao Y. Osterix inhibits bone destruction in osteosarcoma through transcriptional repression of interleukin-1α expression [dissertation]. Houston (TX): The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences; 2006.
20. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998;76:418-22.
21. Weber KL, Doucet M, Price JE, et al. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mouse. Cancer Res 2003;63:2940-7.